Guardant Health (GH) offers non-invasive cancer diagnosis tests and is based out of the U.S.Â The company has seen its stock rally 15% since its Q3 results were announced.Â The company reported strong results in Q3 with sales growth coming in at $61 Mil – a 181% jump year-on-year.Â Earnings loss for the company also narrowed to -$0.14 per share – much better than the consensus estimate of -$0.37. Additionally, the company raised its revenue guidance for full-year 2019 to the $202-$207 Mil range from $180-$190 Mil.
We step back from these recent swings to review Guardant HealthâsÂ performance over the last few years, as a context for what might come next. Our Interactive dashboard – Why has Guardant Health rallied by 15% in the last 20 days?,Â reviews the near term reasons and the big picture.
The context for the last few years:
A closer look At Guardant Health’s Total Revenues over the last few years and the outlook.
Total Revenues for Guardant Health substantially increased from $49.8 Mil in 2017 to $90.6 Mil in 2018; an increase of 81.9%. (Increase is on account of higher volumes of Guardant360 Oncology Test)
This compares with Total Revenues growth of 97.4% in 2017. (Increase is on account of higher volumes of Guardant360 Oncology Test)Â We expect Total Revenues growth to be 127.3% in 2019 (on account of approval for Liquid Biopsy Testing).
A closer look At Guardant Health’s Total ExpensesÂ over the last few years and the outlook
Total Expense for Guardant Health substantially increased from $133 Mil in 2017 to $175 Mil in 2018; an increase of 31.4%.
This compares with Total Expense growth of 86.4% in 2017. We expect Total Expense growth to be 66.2% in 2019.
How doesÂ Guardant Health’s Revenue Growth compare with rivals?
For more information on how Guardant Health’sÂ revenue growth compares with Alnylam Pharmaceuticals, Alkermes and Agios Pharmaceuticals, view our interactive dashboard analysis.
How has Â Guardant Health’s EBT trended?
LBT for Guardant Health increased marginally by 1.21% from $83.2 Mil in 2017 to $84.2 Mil in 2018.
We expect LBT to increase by 0.5% to $84.2 Mil in 2019.
How has Guardant Health’s Net Income and EPS trended?
For more details aboutÂ Guardant Health’s Net Income and EPS, view our interactive dashboard analysis.
Whatâs behind Trefis? See How itâs Powering New Collaboration and What-Ifs
ForÂ CFOs and Finance TeamsÂ |Â Product, R&D, and Marketing Teams
More Trefis Data
Like our charts? ExploreÂ example interactive dashboardsÂ and create your own.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Latest Stocks Videos
- How To Tell When The Stock Market Will Stop Falling, And What To Do When That Happens
- Coronavirus Stocks To Buy – 2 Types Of Investing Opportunities During The Outbreak
- Aurora Cannabis (ACB) Stock Gets a Recession Boost; What’s Next?
- Coronavirus Is Forcing Companies to Suspend Dividends and Cancel Stock Buybacks